{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:23:08Z","timestamp":1778916188448,"version":"3.51.4"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Telbivudine is a novel nucleoside drug recently approved for the treatment of patients with chronic hepatitis B. Its nonclinical safety was evaluated in a comprehensive program of studies, including safety pharmacology, acute and chronic toxicity, reproductive and developmental toxicity, genotoxicity, and carcinogenicity. There were no test article-related effects observed in an in vitro hERG assay or in a core battery of safety pharmacology studies (central nervous system, respiratory, and cardiovascular safety pharmacology studies). Telbivudine was well tolerated in rats and in monkeys following single oral doses up to 2,000 mg\/kg\/day. Except for equivocal axonopathic findings in monkeys and occasional incidences of emesis, soft feces, and minor changes in body weight and food consumption, there was no target organ toxicity observed in mice, rats, or monkeys following oral administration for up to 3, 6, or 9 months, respectively, at doses up to 3,000 mg\/kg\/day. Axonopathy in the sciatic nerves and in the spinal cords of monkeys dosed at 1,000 mg\/kg\/day observed in a 9-month study was considered equivocal, as the role of telbivudine in the injury could not be determined. Slightly higher incidences of abortion and premature delivery observed in rabbits dosed at 1,000 mg\/kg\/day were considered secondary to maternal toxicity. There was no evidence of genotoxicity or carcinogenicity. These results suggest that telbivudine has a favorable safety profile and support its use in patients with chronic compensated hepatitis B viral infection.<\/jats:p>","DOI":"10.1128\/aac.00029-08","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T00:44:15Z","timestamp":1210639455000},"page":"2521-2528","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["Nonclinical Safety Profile of Telbivudine, a Novel Potent Antiviral Agent for Treatment of Hepatitis B"],"prefix":"10.1128","volume":"52","author":[{"given":"Edward G.","family":"Bridges","sequence":"first","affiliation":[{"name":"Idenix Pharmaceuticals, Inc., One Kendall Square, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules R.","family":"Selden","sequence":"additional","affiliation":[{"name":"Idenix Pharmaceuticals, Inc., One Kendall Square, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouqi","family":"Luo","sequence":"additional","affiliation":[{"name":"Idenix Pharmaceuticals, Inc., One Kendall Square, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00399.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.716-723.2002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/infdis\/167.1.21","volume":"167","year":"1993","unstructured":"Browne, M. J., K. H. Mayer, S. B. D. Chafee, M. N. Dudley, M. R. Posner, S. M. Steinberg, K. K. Graham, S. M. Geletko, S. H. Zinner, S. L. Denman, L. M. Dunkle, K. Sanjeev, C. McLaren, G. Skowron, N. M. Kouttab, T. A. Kennedy, A. B. Weitberg, and G. A. Curt. 1993. 2\u2032,3\u2032-Didehydro-3\u2032-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J. Infect. Dis.167:21-29.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.229-235.2001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)00836-5"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117698"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/tera.1420460406","volume":"46","year":"1992","unstructured":"Feussner, E. L., G. E. Lightkep, R. A. Hennesy, A. M. Hoberman, and M. S. Christian. 1992. A decade of rabbit fertility data: study of historical control animals. Teratology46:349-365.","journal-title":"Teratology"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-10-199305150-00002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.039"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1096\/fasebj.2.7.3280378","volume":"2","year":"1988","unstructured":"Goldstein, R. S., J. B. Tarloff, and J. B. Hook. 1988. Age-related nephropathy in laboratory rats. FASEB J.2:2241-2251.","journal-title":"FASEB J."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/01926230490422574","volume":"32","year":"2004","unstructured":"Hard, G. C., and K. N. Khan. 2004. A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Toxicol. Pathol.32:171-180.","journal-title":"Toxicol. Pathol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1728-1733.2002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1293\/tox.16.267","volume":"16","year":"2003","unstructured":"Kanno, H., Z. Y. Tanakamaru, Y. Ishimura, H. Kandori, H. Yamasaki, and S. Sasaki. 2003. Historical background data in CB6F1-tg-rasH2 mice and CB6F1-nonTg-rasH2 mice over a 26-week experimental period. J. Toxicol. Pathol.16:267-274.","journal-title":"J. Toxicol. Pathol."},{"key":"e_1_3_2_15_2","first-page":"34","volume":"357","year":"2007","unstructured":"Lai, C. L., E. Gane, Y. F. Liaw, C. W. Hsu, S. Thongsawat, Y. Wang, Y. Chen, E. J. Heathcote, J. Rasenack, N. Bzowej, N. V. Naoumov, A. M. Di Bisceglie, S. Zeuzem, Y. M. Moon, Z. Goodman, G. Chao, B. Fielman Constance, N. A. Brown, and the GLOBE Study Group. 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med.357:34-46.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.2061"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058119"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21513"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM199510263331702","volume":"333","year":"1995","unstructured":"McKenzie, R., M. W. Fried, R. Sallie, H. Conjeevaram, A. M. Di Bisceglie, Y. Park, B. Savarese, D. Kleiner, M. Tsokos, C. Luciano, T. Pruett, J. L. Stotka, S. E. Straus, and J. H. Hoofnagle. 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med.333:1099-1105.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.8.1824"},{"key":"e_1_3_2_21_2","first-page":"127","year":"1990","unstructured":"Montgomery, C. A., and J. C. Seely. 1990. Kidney, p. 127-153. In G. A. Boorman, S. L. Eustis, M. R. Elwell, C. A. Montgomery, and W. F. MacKenzie (ed.), Pathology of the Fischer rat. References and atlas. Academic Press, San Diego, CA.","journal-title":"Pathology of the Fischer rat."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/01926230252824851","volume":"30","year":"2002","unstructured":"Morton, D., C. L. Alden, A. J. Roth, and T. Usui. 2002. The Tg rasH2 mouse in cancer hazard identification. Toxicol. Pathol.30:139-146.","journal-title":"Toxicol. Pathol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.496-503.2000"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/019262338601400111","volume":"14","year":"1986","unstructured":"Peter, C. P., J. D. Burek, and M. J. van Zwieten. 1986. Spontaneous nephropathies in rats. Toxicol. Pathol.14:91-100.","journal-title":"Toxicol. Pathol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707233170402"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020101200205"},{"key":"e_1_3_2_27_2","first-page":"191","volume":"31","year":"2003","unstructured":"Takaoka, M., S. Sehata, T. Maejima, T. Imai, M. Torii, H. Satoh, K. Toyosawa, Z.-Y. Tanakamaru, T. Adachi, S. Hisada, M. Ueda, H. Ogasawara, M. Matsumoto, K. Kobayashi, M. Mutai, and T. Usui. 2003. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. Toxicol. Pathol.31:191-199.","journal-title":"Toxicol. Pathol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MOG.0b013e328049ddc1","volume":"23","year":"2007","unstructured":"Tan, J., and A. S. Lok. 2007. Update on viral hepatitis: 2006. Curr. Opin. Gastroenterol.23:263-267.","journal-title":"Curr. Opin. Gastroenterol."},{"key":"e_1_3_2_29_2","first-page":"90","volume":"29","year":"2007","unstructured":"Usui, T., M. Mutai, S. Hisada, M. Takoaka, K. A. Soper, B. McCullough, and C. Alden. 2007. CB6F1-rasH2 mouse: overview of available data. Toxicol. Pathol.29:90-108.","journal-title":"Toxicol. Pathol."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/0140-6736(90)92085-V","volume":"336","year":"1990","unstructured":"Yarchoan, R., J. M. Pluda, R. V. Thomas, H. Mitsuya, P. Brouwers, K. M. Wyvill, N. Hartman, D. G. Johns, and S. Broder. 1990. Long-term toxicity\/activity profile of 2\u2032,3\u2032-dideoxyinosine in AIDS or AIDS-related complex. Lancet336:526-529.","journal-title":"Lancet"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652407780059159"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01313-05"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00029-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00029-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:43:12Z","timestamp":1645472592000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00029-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1128\/AAC.00029-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00029-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"2008-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-05-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}